---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022318"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:24:11.092451+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evofem posts Q3 2025 operating income of $1.0M; net sales up 10% YoY to $5.0M

## Summary
- Net sales $5.0M in Q3 2025 vs $4.5M Q3 2024; operating income $1.0M vs loss of $2.4M.
- Net loss attributable to common stockholders $1.7M ($0.01 per share) vs $2.4M ($0.02) prior year.
- Total operating expenses decreased 42% to $4.0M, helped by $1.9M gain from change in Rush royalty estimate.
- Terminated merger with Aditxt after stockholders did not approve the deal at Oct 20 special meeting.
- Advancing manufacturing cost reduction targeting ~50% lower COGS for both PHEXX and SOLOSEC.

## SEC filing metadata
- accession: 0001493152-25-022318
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/0001493152-25-022318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022318
- JSON: https://secwatch.observer/filing/0001493152-25-022318.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.